Skip to main content
TipRanks
Go Ultimate75% OFF

Pacira Pharmaceuticals (82P) Stock Price & Analysis

0 Followers

82P Stock Chart & Stats

No data to display
Day’s Range
N/A
52-Week Range
N/A
Previous Close
N/A
Volume
N/A
Average Volume (3M)
N/A
Market Cap
CHF 1.23B
Enterprise Value
CHF 1.07B
Total Cash (Recent Filing)
CHF 295.58M
Total Debt (Recent Filing)
CHF 340.28M
Price to Earnings (P/E)
―
Beta
N/A
Next Earnings
Mar 04, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Substantially Improved Balance Sheet

Debt reduction from roughly $1.13B to $340M and a very low reported debt-to-equity level materially improve financial flexibility. This lowers balance-sheet pressure and leaves more capacity to fund commercialization and pipeline work through normal operating cycles.

Strong Cash Generation

Consistent operating cash flow and $169M of TTM free cash flow indicate strong conversion of accounting earnings into internally generated funds. That supports investment in products and studies, strengthens liquidity, and reduces reliance on additional borrowing.

Expanding Payer Access

Broader reimbursement and preferred formulary placement can remove barriers to physician adoption and institutional purchasing. Coverage across roughly 150 million lives strengthens the commercial foundation for EXPAREL and ZILRETTA beyond any single quarter.

Bears Say

Sharp TTM Revenue Contraction

A 38.4% TTM revenue decline signals that recent profitability has not yet been matched by durable top-line momentum. Continued contraction could reduce operating leverage, weaken reinvestment capacity, and make future growth more dependent on new indications or products.

Gross Margin Pressure And Rising Expenses

Lower gross margin combined with higher research and selling costs can compress earnings even when product sales grow. If this pattern persists, Pacira may have less operating leverage to convert commercial progress and pipeline investment into durable bottom-line improvement.

EXPAREL Royalty Dispute Remains Unresolved

The partial reversal creates continuing legal and financial uncertainty around EXPAREL royalties, including the amount of any eventual obligation. A remand could produce additional costs and distract management while reducing confidence in the product's future cash economics.

Pacira Pharmaceuticals News

82P FAQ

What is Pacira Pharmaceuticals’s market cap?
Pacira Pharmaceuticals’s market cap is CHF1.23B.
When is Pacira Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Pacira Pharmaceuticals’s earnings last quarter?
Pacira Pharmaceuticals released its earnings results on Oct 29, 2026. The company reported CHF0.587 earnings per share for the quarter, missing the consensus estimate of CHF0.638 by -CHF0.051.
Is Pacira Pharmaceuticals overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Pacira Pharmaceuticals pay dividends?
Pacira Pharmaceuticals does not currently pay dividends.
What is Pacira Pharmaceuticals’s EPS estimate?
Pacira Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
What happened to Pacira Pharmaceuticals’s price movement after its last earnings report?
Pacira Pharmaceuticals reported an EPS of CHF0.587 in its last earnings report, missing expectations of CHF0.638. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of Pacira Pharmaceuticals?
Hedge funds hold Pacira Pharmaceuticals shares: the largest hedge-fund position in Pacira Pharmaceuticals is 1,230,135,030 shares, and hedge funds decreased their holdings by 21.3K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology